85 related articles for article (PubMed ID: 1640482)
1. Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro.
Hersh EM; Gschwind CR; Taylor CW; Dorr RT; Taetle R; Salmon SE
J Natl Cancer Inst; 1992 Aug; 84(16):1238-44. PubMed ID: 1640482
[TBL] [Abstract][Full Text] [Related]
2. Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent.
Evens AM; Prachand S; Shi B; Paniaqua M; Gordon LI; Gartenhaus RB
Clin Cancer Res; 2004 Feb; 10(4):1481-91. PubMed ID: 14977852
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423.
Dorr RT; Wisner L; Samulitis BK; Landowski TH; Remers WA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1039-49. PubMed ID: 22186884
[TBL] [Abstract][Full Text] [Related]
4. Induction of mitochondrial changes in myeloma cells by imexon.
Dvorakova K; Waltmire CN; Payne CM; Tome ME; Briehl MM; Dorr RT
Blood; 2001 Jun; 97(11):3544-51. PubMed ID: 11369649
[TBL] [Abstract][Full Text] [Related]
5. Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon.
Dvorakova K; Payne CM; Tome ME; Briehl MM; McClure T; Dorr RT
Biochem Pharmacol; 2000 Sep; 60(6):749-58. PubMed ID: 10930529
[TBL] [Abstract][Full Text] [Related]
6. Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines.
Scott J; Dorr RT; Samulitis B; Landowski TH
Cancer Chemother Pharmacol; 2007 May; 59(6):749-57. PubMed ID: 17333195
[TBL] [Abstract][Full Text] [Related]
7. Correlates of imexon sensitivity in human multiple myeloma cell lines.
Samulitis BK; Landowski TH; Dorr RT
Leuk Lymphoma; 2006 Jan; 47(1):97-109. PubMed ID: 16321833
[TBL] [Abstract][Full Text] [Related]
8. Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells.
Dvorakova K; Payne CM; Landowski TH; Tome ME; Halperin DS; Dorr RT
Anticancer Drugs; 2002 Nov; 13(10):1031-42. PubMed ID: 12439337
[TBL] [Abstract][Full Text] [Related]
9. Suppression of human lymphoma development in the severe combined immune-deficient mouse by imexon therapy.
Hersh EM; Grogan TM; Funk CY; Taylor CW
J Immunother Emphasis Tumor Immunol; 1993 Feb; 13(2):77-83. PubMed ID: 8391308
[TBL] [Abstract][Full Text] [Related]
10. Treatment of the murine, retrovirus-induced lymphoproliferative immunodeficiency disease (LP-BM5) in C57BL/10 mice with the immunomodulator Imexon.
Funk CY; Eisman J; Hersh EM
AIDS Res Hum Retroviruses; 1992 May; 8(5):633-8. PubMed ID: 1515214
[TBL] [Abstract][Full Text] [Related]
11. Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines.
Dorr RT; Raymond MA; Landowski TH; Roman NO; Fukushima S
Int J Gastrointest Cancer; 2005; 36(1):15-28. PubMed ID: 16227632
[TBL] [Abstract][Full Text] [Related]
12. Chemistry and pharmacology of imexon and related cyanoaziridines.
Remers WA; Dorr RT
Curr Med Chem; 2012; 19(33):5745-53. PubMed ID: 22998528
[TBL] [Abstract][Full Text] [Related]
13. Imexon augments sensitivity of human lymphoma cells to ionizing radiation: in vitro experimental study.
Cho H; Koto M; Riesterer O; Molkentine DP; Giri U; Milas L; Story MD; Ha CS; Raju U
Anticancer Res; 2009 Nov; 29(11):4409-15. PubMed ID: 20032386
[TBL] [Abstract][Full Text] [Related]
14. Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma.
Moehler TM; Feneberg R; Ho AD; Golenkov AK; Ludwig H; Kropff M; Khuageva NK; Hajda J; von Broen I; Goldschmidt H
Anticancer Drugs; 2010 Aug; 21(7):708-15. PubMed ID: 20571355
[TBL] [Abstract][Full Text] [Related]
15. Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice.
Pourpak A; Meyers RO; Samulitis BK; Sherry Chow HH; Kepler CY; Raymond MA; Hersh E; Dorr RT
Anticancer Drugs; 2006 Nov; 17(10):1179-84. PubMed ID: 17075317
[TBL] [Abstract][Full Text] [Related]
16. Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells.
Dvorakova K; Payne CM; Tome ME; Briehl MM; Vasquez MA; Waltmire CN; Coon A; Dorr RT
Mol Cancer Ther; 2002 Jan; 1(3):185-95. PubMed ID: 12467213
[TBL] [Abstract][Full Text] [Related]
17. Preclinical pharmacokinetics and antitumor activity of imexon.
Dorr RT; Liddil JD; Klein MK; Hersh EM
Invest New Drugs; 1995; 13(2):113-6. PubMed ID: 8617572
[TBL] [Abstract][Full Text] [Related]
18. Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells.
Samulitis BK; Dorr RT; Chow HH
Anticancer Res; 2011 Sep; 31(9):2781-5. PubMed ID: 21868520
[TBL] [Abstract][Full Text] [Related]
19. Novel antitumor 2-cyanoaziridine-1-carboxamides.
Iyengar BS; Dorr RT; Alberts DS; Hersh EM; Salmon SE; Remers WA
J Med Chem; 1999 Feb; 42(3):510-4. PubMed ID: 9986721
[TBL] [Abstract][Full Text] [Related]
20. Elucidation of mode of retroviral-inhibitory effects of imexon through use of immune competent and severe combined immune deficiency (SCID) mice.
Morrey JD; Mead JR; Warren RP; Okleberry KM; Burger RA; Sidwell RW
Antiviral Res; 1992 Mar; 17(3):223-33. PubMed ID: 1314537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]